Návratnosť kapitálu spoločnosti Navidea Biopharmaceuticals Inc
Aká je hodnota metriky Návratnosť kapitálu spoločnosti Navidea Biopharmaceuticals Inc?
Hodnota metriky Návratnosť kapitálu spoločnosti Navidea Biopharmaceuticals Inc je 4,619.50%
Aká je definícia metriky Návratnosť kapitálu?
Return on capital employed (ROCE) je finančný ukazovateľ, ktorý meria rentabilitu spoločnosti a účinnosť spoločnosti vo využívaní vlastného kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnosť kapitálu spoločností v sektore Health Care sektor na NYSEMKT v porovnaní so spoločnosťou Navidea Biopharmaceuticals Inc
Čomu sa venuje spoločnosť Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Firmy s metrikou návratnosť kapitálu podobnou spoločnosti Navidea Biopharmaceuticals Inc
- Hodnota metriky Návratnosť kapitálu spoločnosti GTPL Hathway je 3,515.44%
- Hodnota metriky Návratnosť kapitálu spoločnosti VBI Vaccines je 3,542.31%
- Hodnota metriky Návratnosť kapitálu spoločnosti North European Oil Royalty Trust je 3,719.06%
- Hodnota metriky Návratnosť kapitálu spoločnosti Pasofino Gold je 3,729.38%
- Hodnota metriky Návratnosť kapitálu spoločnosti Synthesis Systems je 3,846.25%
- Hodnota metriky Návratnosť kapitálu spoločnosti PhaseBio Pharmaceuticals je 4,146.52%
- Hodnota metriky Návratnosť kapitálu spoločnosti Navidea Biopharmaceuticals Inc je 4,619.50%
- Hodnota metriky Návratnosť kapitálu spoločnosti SRAX Inc je 4,628.38%
- Hodnota metriky Návratnosť kapitálu spoločnosti Blue Apron Inc je 5,016.13%
- Hodnota metriky Návratnosť kapitálu spoločnosti ParkerVision je 5,589.92%
- Hodnota metriky Návratnosť kapitálu spoločnosti Asensus Surgical Inc je 5,861.92%
- Hodnota metriky Návratnosť kapitálu spoločnosti Whiting USA Trust II je 7,251.43%
- Hodnota metriky Návratnosť kapitálu spoločnosti Astra je 7,618.05%